IM Cannabis Corp (IMCC-CN) Stock Price and News - The Globe and Mail

TOP STORIES: IM Cannabis Corp

IM Cannabis Announces Plans to Voluntarily Delist from the Canadian Securities Exchange

IM Cannabis Provides Corporate Updates

IM Cannabis Reports First Quarter Financial Results

IM Cannabis Announces Filing of Information Circular for Upcoming Annual General and Special Meeting and Provides Additional Information on the Focus Transaction

IM Cannabis to Report First Quarter 2025 Financial Results on Thursday, May 15th at 9:00am ET

IM Cannabis Provides Corporate Updates

IM Cannabis Reports Fourth Quarter and Full Year 2024 Financial Results

IM Cannabis to Report Fourth Quarter and Full Year 2024 Financial Results on Monday, March 31 2025 at 9:00am ET

IM Cannabis Announces Change of Auditors

January 17, 2025

IM Cannabis Reports Third Quarter Financial Results

November 14, 2024

IM Cannabis Closes Non-Brokered Private Placement led by Management and Concurrent Debt Settlement

November 12, 2024

IM Cannabis to Report Third Quarter 2024 Financial Results on Thursday, November 14th at 9:00am ET

November 6, 2024

IM Cannabis Announces up to US$1,613,000 Private Placement Offering Led by Management

October 4, 2024

IMC Germany Announces Outstanding Preliminary Q3, 2024 Performance with 50% Growth Over Q2

October 2, 2024

IM Cannabis Announces Appointment of Shmulik Arbel to Board of Directors

September 11, 2024

IM Cannabis Reports Second Quarter Financial Results

August 14, 2024

IM Cannabis to Report Second Quarter 2024 Financial Results on Wednesday, August 14th at 9:00am ET

IM Cannabis Receives NASDAQ Notification of Regaining Compliance with Nasdaq's Minimum Bid Price Requirement

IM Cannabis Shares Commence Trading on 6:1 Consolidated Basis

IM Cannabis Announces Intention to Complete Consolidation

IMCC Addresses Accelerated Growth in Germany Through new Supply Agreement with EU-GMP Certified Glasshouse Botanics and Announces a Change to its Board of Directors

IM Cannabis Closes Convertible Debenture Offering to Support Accelerated Growth in Germany

IMC announces the termination of a preliminary term sheet with Kadimastem Ltd., a public company traded on the Tel Aviv Stock Exchange to fully focus on the recently legalized German market

IM Cannabis Reports First Quarter Financial Results

IM Cannabis to Report First Quarter 2024 Financial Results on Wednesday, May 8th at 9:00am ET

IMC to transfer its Oranim Pharmacy shares back to the seller

IM Cannabis and Flora Growth Partner to Bring Vessel Cannabis Accessories to the Israeli Market

Avant and IMC Execute BLK MKT™ Trademark Licensing Agreement for the German Medical Cannabis Market

IMC applauds the April 1st implementation of the new Israeli cannabis regulation, facilitating access for many new patients

IM Cannabis Reports 2023 Financial Results

IMC Expects Accelerated Growth in Germany from the Country's Groundbreaking Cannabis Legalization

IM Cannabis to Report Fourth Quarter and Full Year 2023 Financial Results on Thursday, March 28 at 9:00am ET

Profile

IM Cannabis Corp is a Canada-based international medical cannabis company. It operates in the field of medical cannabis, through Focus Medical Herbs Ltd. (Focus), which holds a cultivation license to breed, grow, and supply medical cannabis products The majority of its revenues are generated from sales of medical cannabis products to customers in Israel. The remaining revenues are generated from sales of medical cannabis, as well as other products, to customers in Germany. Geographically, the majority is from Israel.